Correlative analysis of the SARC028 trial tumors demonstrated higher densities of activated T cells (CD8+ CD3+ PD-1+), cytotoxic T cells, regulatory T cells and increased percentage of tumor-associated macrophages (TAM) expressing PD-L1 pre-treatment in responders to ICI compared with non-responders [44]. This evidence concerns the gene PDCD1 and neoplasm.